Research Article - Neuropsychiatry (2017) Volume 7, Issue 6
Do Vesicular Monoamine Transporter 2 Genotypes Relate to Obesity and Eating Behavior?
- Corresponding Author:
- Orçun Avşar
Department of Biotechnology
Yeditepe University, Istanbul, Turkey
Genetic factors contribute to development of obesity and eating behavior. Vesicular monoamine transporter 2 (VMAT2, SLC18A2) gene is a dopaminergic system gene that regulates dopamine neurotransmission, and may be a part of the pathogenesis of obesity and eating behavior. No previous studies have analyzed VMAT2 polymorphisms about obesity and eating behavior. In the current study, we investigated the association of rs363399 and rs4752045 with adult obesity and eating behavior in 448 subjects. No genetic association was found for VMAT2 polymorphisms and obesity. On the other hand, the C/C genotype of rs363399 and the C/G genotype of rs4752045 were significantly associated with eating behavior, particularly ‘eating for reward’ and significantly higher in obesity group (p<0.001). These results suggested that C/C and C/G genotypes might have an effect on eating behavior
(‘eating for need’ vs ‘eating for reward’) and might be involved in the development of obesity in an indirect way. Future studies are needed to replicate these findings in other populations.
Obesity, Dopamine, VMAT2, Eating behavior
Obesity is a medical problem in which excess body fat has accumulated to the extent that it may impair health and body mass index (BMI) is the main indicator for the identification of obesity . Obesity is a multifactorial medical condition and affected by several factors such as genetic makeup, epigenetic changes, environment, diet, and exercise .
Dopamine (DA) is a neuromodulator and involved in normal brain functions such as attention, working memory, and reinforcement learning . Disturbances in dopaminergic neurotransmission is implicated in the pathogenesis of neuropsychiatric disorders such as addiction, depression, schizophrenia, and eating disorders . Obesity is associated with alterations in striatal dopamine signaling. For instance, dopamine dysregulation, specially dopamine receptor 2 (DRD2) signaling, is correlated with development of obesity in humans and rodents .
Vesicular monoamine transporter 2 (VMAT2) in the central nervous system is an essential protein for dopamine neurotransmission . VMAT2 packages dopamine into vesicles and helps transport it to the extracellular medium and provides the homeostasis of dopamine in the cytoplasm. VMAT2 dysfunction causes to excessive dopamine accumulation in the cytoplasm and then, free radicals are generated by the metabolism of dopamine .
The human VMAT2 gene composes of 16 exons and 15 introns and localized on chromosome 10 . Polymorphisms in the brain form of VMAT2 gene or in its regulatory regions which affect its expression or protein function may therefore serve as genetic risk factor for diseases related with distrupted dopamine neurotransmission. We hypothesized that VMAT2 polymorphisms might be risk factors for obesity and eating behavior. In the present study, we aim to analyze the relationship between the gene variants of VMAT2 and obesity and eating behavior. We were interested in the transporter protein (VMAT2) in order to find out the mechanism of obesity via dopamine neurotransmission. There is no report of the associations between VMAT2 polymorphisms and obesity and eating behavior. We expect that our findings might be helpful for understanding the role of DA in the pathogenesis of obesity and eating behavior then these results might alter the treatment of obesity and its complications and eating behavior according to the DA neurotransmission.
Subjects and Methods
In this study, we have investigated the polymorphisms of VMAT2 gene in 2 groups. Group 1 (n=234) whose mean age was 31.4 ± 7.8 years contained overweight and individuals with obesity and the mean BMI was 33.8 ± 8.7 kg/m2 (Table 1). The control group selected from healthy individuals (n=214) whose BMI were between 18.50 and 24.99. The mean age of the healthy group was 27.6 ± 5.8 years and the mean BMI was 21.7 ± 1.9 kg/m2 (Tables 1-3). Inclusion criteria were: 1.giving informed consent, 2. age between 20 and 48 years, 3. 25≤BMI<30 for overweight and ≥ 30 for obese group; BMI: 18.50-24.99 for control group. Exclusion criteria were: 1. previous use substance of abuse, 2. having a neurological or psychiatric disorder, 3. being pregnant or nursing, 4. being chronic alcoholic, 5. smoking, 6. using antihypertensive beta-blocker, 7. being menopausal, 8. having thyroid or diabetes problem 9. oral contraceptive usage. Permission for research was granted by the Bioethics Committee of Yeditepe University, Istanbul, Turkey (Decree no: 411, date of approval: 22/04/2014). Both men and women of Turkish origin, all volunteers, were collected at the Department of Endocrinology and Metabolism Disorders at Fatih Sultan Mehmet Education and Research Hospital in Istanbul, Turkey. All volunteers were measured and weighed with standard medical device. Informed written consent was obtained from all subjects according to the Declaration of Helsinki guidelines. We had face-to-face interviews with all of the participants during the period of August, 2014 and February, 2015. The participants reported motivations for food using a modified version of Testing of the Eating Motivation Survey (TEMS) .
|Characteristic||Controls (n=214)||Patients (n=234)||p-value OR NS|
|Female||n=166 (54.2%)||n=140 (45.8%)||<0.001|
|Male||n=48 (33.8%)||n=94 (66.2%)||<0.001|
|Age (years)||27.8 ± 5.9||31.4 ± 7.9||<0.001|
|BMI (kg/m2)||21.7 ± 1.9||34.4 ± 8.7||<0.001|
|Yes||n=82 (36.6%)||n=142 (63.4%)||0.815|
|No||n=132 (59%)||n=92 (41%)|
Table 1: Demographic characteristics of the study population.
|Controls (n=214)||Patients (n=234)||p value|
|T/T||n=150 (70%)||n=179 (76.4%)|
|T/C||n=45 (21%)||n=36 (15.4%)|
|C/C||n=19 (9%)||n=19 (8.2%)|
|T||n=345 (80.6%)||n=394 (84.1%)|
|C||n=83 (19.4%)||n=74 (15.9%)|
|C/C||n=97 (45.3%)||n=121 (51.7%)||0.222|
|C/G||n=94 (43.9%)||n=84 (35.8%)|
|G/G||n=23 (10.7%)||n=29 (12.5%)|
|C||n=288 (67.2%)||n=326 (69.6%)|
|G||n=140 (32.8%)||n=142 (30.4%)|
Table 2: Genotype and allele frequencies of rs363399 and rs4752045 in the study groups.
|rs363399 and Age T/T||3.28||1||0.04||0.634 (1.211-1.434)|
|rs4752045 and Age C/G||2.23||1||0.02||1.123 (0.645-1.146)|
|rs363399 and Sex|
|rs4752045 and Sex|
|rs363399 and BMI|
|rs4752045 and BMI|
|rs363399 and EB|
|rs4752045 and EB|
EB: Eating behavior (‘eating for need’ vs ‘eating for reward’
Table 3: The chi-square (x2), degree of freedom (df), p, odds ratio (OR), and confidence interval (95% CI) values between control and patient groups according to VMAT2 polymorphisms [rs363399 (T/C) and rs4752045 (C/G)] and demographic characteristics (The reference category is control).
DNA extraction was performed from peripheral blood samples which were recruited in tubes including ethylenediaminetetraacetic acid (EDTA). For DNA extraction, the DTAB-CTAB (Sigma-Aldrich, Taufkirchen, Germany) DNA extraction method was used. Purity was compared based on A260/A280 absorbance ratios in the range of 1.7-1.9. The single nucleotide polymorphisms (SNPs) of VMAT2 were genotyped using Touchdown Polymerase Chain Reaction (PCR) with proper primers. The sequence of forward primer is 5’-GCTCACGCCCAGGAAAGT-3’, and reverse primer is 5’-TCCGCTTGTCAAAATTCTTAGGT-3’ (rs363399). The sequence of forward primer is 5’-CACCATGTTCCTGTTTCAGCC-3’, and reverse primer is 5’-TGGCAGGAGACAGTTTCTCCA-3’ (rs4752045).
The map of the restriction enzyme was found by the use of NEBcutter V2.0 program and the proper enzyme was selected according to the recognition sequence. The PCR products of rs363399 (T/C) and rs4752045 (C/G) were cleaved by using MspI, and AciI restriction enzymes, respectively. The restriction products were determined by agarose gel electrophoresis which was stained with ethidium bromide and then, visualized under ultraviolet light. The restriction fragments for C/C genotype were 47and 45 bp; for T/T genotype was 92 bp; for C/T genotype were 92, 47, and 45 bp (rs363399). The restriction fragments for C/C genotype was 80 bp; for G/G genotype were 48 and 32 bp; for C/G genotype were 80, 48, and 32 bp (rs4752045).
The statistical assessment of our study was carried out by the use of SPSS (Statistical Package for the Social Sciences) version 24.0 (Chicago, IL, USA). The differences of genotype between control and patient groups were analyzed by Chi-square, Fisher’s Exact test. Pearson x2 test was used for the determination of the deviation from Hardy-Weinberg equilibrium (p<0.05). The effects of genotypes and alleles on eating behavior were analyzed by one-way Anova test. Allele frequencies were computed according to gene counting method. Logistic regression was used in order to calculate odds ratios (ORs) and confidence interval (CI) values. P values which were under 0.05 were considered significant.
We have investigated the polymorphisms of VMAT2 gene in 2 groups. The control and obese groups were analyzed for age, sex, BMI, family history, eating behavior and VMAT2 genotypes. Eating behavior was divided into two groups: ‘eating for need’ and ‘eating for reward’. Eating behavior was evaluated according to ‘eating for need’ as a reference.
It has been designated that age, sex, BMI were significantly different in control and obese groups. It has been demonstrated that there was no significance for family history between case and control groups. When the obese and control groups were compared, it was reported that there was no significant association between VMAT2 genotypes and obesity. The p value between patient and control groups about genotype frequencies of rs363399 was 0.26. The p value between patient and control groups about genotype frequencies of rs4752045 was 0.22. On the contrary, T/T genotype of rs363399 was significantly associated with age in obese group (p=0.04). Furthermore, C/G genotype of rs4752045 was significantly correlated with age in case group (p=0.02). T/C genotype of rs363399 was significantly associated with sex (female/male) in obesity (p=0.03). BMI and C/G genotype of rs4752045 was significantly associated with each other in patients (p=0.001). Moreover, C/C genotype of rs363399 was significantly associated with eating behavior, particularly ‘eating for reward’, and significantly higher in obese group (p<0.001). C/G genotype of rs4752045 was significantly associated with ‘eating for reward’ and significantly higher in patient group (p<0.001).
To our knowledge, this is the first study designed to investigate the association between VMAT2 polymorphisms and obesity and eating behavior (‘eating for need’ and ‘eating for reward’). We suggested that polymoprhisms which may alter expression or fuction of VMAT2 gene may be effective in the development of obesity. Therefore, this study elucidated the relationships between VMAT2 genotypes, obesity, and eating behavior in a population residing in Turkey. But further studies are required to rebut or affirm these observations.
Brighina, et al. have investigated the association of VMAT2 gene polymorphisms and Parkinson’s disease and it has been reported that only two SNPs in the promoter region (rs363371 and rs363324) was related with PD . In previous studies, VMAT2 gene polymorphisms has been reported to be associated with initial symptom of rigidity/bradykinesia, tardive dyskinesia, alcohol dependence, PD, and cognition [10-14].
rs363399 and rs4742045 polymorphisms occur in intron 2 and intron 7, respectively. These two polymorphisms were exclusively analyzed in a depression study and it has been reported that there was a correlation with depression .
The C/C genotype of proportion of the VMAT2 rs363399 reported in this study was significantly higher in the obesity group who ate for reward when compared with healthy individuals. Furthermore, the C/G genotype proportion of the VMAT2 rs4752045 was significantly higher in the case group who ate for reward according to the control group. These findings may demonstrate that C/C and C/G genotypes might have an effect on eating behavior (‘eating for need’ vs ‘eating for reward’) and might be involved in the pathogenesis of obesity in an indirect way. In our previous study, it has been demonstrated that eating for reward might be correlated with adult obesity due to altered dopamine neurotransmission .
When the groups were compared for VMAT2 genotypes, there was no association between genotypes and obesity. From the foregoing, we may infer that some environmental factors might have a mediating role in the interaction between VMAT2 rs363399, rs4752045 and obesity.
In this study, we reported two SNPs of dopamine-related gene, rs363399 and rs4752045 in VMAT2, did not show any significant associations with obesity in Turkish population. On the other hand, C/C genotype of rs363399 and C/G genotype of rs4752045 were significantly associated with ‘eating for reward’ and these genotypes might affect eating behavior and might be involved in the pathogenesis of obesity. Furthermore, gender, sex, and BMI are the factors that might affect the development of adult obesity.
Strengths and Limitations
The strengths of this study involve a novel research question, and it is the first study which investigates the associations between VMAT2 genotypes, obesity and eating behavior. Several limitations also need to be acknowledged. First of all, it is the first study of its kind, but replication studies are needed in Turkish population and the sample size can be expanded in further studies. Furthermore, other population studies are required. Unfortunately, due to the limited resource, we concentrated on transporter protein, VMAT2, in this study and other transporter protein, DAT, and dopaminedegrading enzymes, MAOA and COMT, in our previous studies. Other dopaminergic genes which affect dopamine function such as tyrosine hydroxylase (TH) and dopamine receptors should be considered in future studies examining the effects of dopaminergic genes, obesity and eating behavior.
We thank all the volunteers for donating blood for the study. All the authors thank the nurses who collected blood from the subjects in a painless way at Fatih Sultan Mehmet Education and Research Hospital.
This research project was supported by Yeditepe University.
Availability of data and materials
All raw data generated or data analyzed during this study are available from the corresponding author upon request.
The authors notify that no conflicts of interest in this work.
Orçun Avşar performed the experiments, statistical analysis and wrote the paper; Ece Genç and Ayşegül Kuşkucu supervised all the study; Seda Sancak recruited the volunteers; all authors read and approved the final manuscript.
- Tanjila TS, Moyenuddin PK. Obesity and disease association: A review. AKMMC. J 1(2), 21-24 (2010).
- Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, et al. Obesity. Nat. Rev. Dis. Primers 17034 (2017).
- Fellous JM, Suri RE. The roles of dopamine. Cambridge: The MIT Press (2002).
- Richter A, Barman A, Wüstenberg T, et al. Behavioral and neural manifestations of reward memory in carriers of low-expressing versus high-expressing genetic variants of the dopamine D2 receptor. Front. Psychol 8(), 654 (2017).
- Ruegsegger GN, Booth FW. Running from disease: Molecular mechanisms associating dopamine and leptin signaling in the brain with physical inactivity, obesity, and type 2 diabetes. Front. Endocrinol 8(1), 109 (2017)
- Glatt CE, Wahner AD, White DJ, et al. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum. Mol. Genetics 15(2), 299-305 (2006).
- Yang X, Xu P, Zhao Q, et al. Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson’s disease in Han Chinese men. Parkinsons Disease (2015).
- Brighina L, Riva C, Bertola F, et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease. Neurobiol. Aging 34(6), e9-13 (2013).
- Renner B, Sproesser G, Strohbach S, et al. Why we eat what we eat. The eating motivation survey (TEMS). Appetite 59(1), 117–128 (2012).
- Hu T, Chen Y, Ou R, et al. Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson’s disease, amyotrphic lateral sclerosis and multiple system atrophy. J. Neurol. Sci 377(1), 65-71 (2017).
- Zai CC, Tiwari AK, Mezzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J. Psych. Res 47(11), 1760-1765 (2013).
- Fehr C, Summerlad D, Sander T, et al. Association of VMAT2 gene polymorphisms with alcohol dependence. J. Neu. Transm 120(8), 1161-1169 (2013).
- Kariya S, Hirano M, Takahashi N, et al. Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson’s disease in Japan. J. Neurol. Sci 232(1-2), 91-94 (2005).
- Markos SM, Failla MD, Ritter AC, et al. Genetic variation in the vesicular monoamine transporter: Preliminary associations with cognitive outcomes after severe traumatic brain injury. J. Head. Trau. Rehab 32(2), E24-E34 (2017).
- Christiansen L, Tan Q, Iachina M, et al. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol. Psych 61(2), 223-30 (2007).
- Avsar O, Kuskucu A, Sancak S, et al. Are dopaminergic genotypes risk factors for eating behavior and obesity in adults. Neurosci. Lett 654(1), 28-32 (2017).